Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Have Conflicting Sentiments on These Healthcare Companies: Arcellx Inc (ACLX), DENTSPLY SIRONA (XRAY) and Personalis (PSNL)

Tipranks - Sat Feb 28, 6:13AM CST

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Arcellx Inc (ACLXResearch Report), DENTSPLY SIRONA (XRAYResearch Report) and Personalis (PSNLResearch Report).

Claim 50% Off TipRanks Premium

Arcellx Inc (ACLX)

Needham analyst Gil Blum maintained a Hold rating on Arcellx Inc today. The company’s shares closed last Thursday at $113.88.

According to TipRanks.com, Blum is a 4-star analyst with an average return of 8.5% and a 40.7% success rate. Blum covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, Mereo Biopharma Group Plc, and Cartesian Therapeutics. ;'>

Arcellx Inc has an analyst consensus of Hold, with a price target consensus of $112.67, a -1.0% downside from current levels. In a report released today, TipRanks – OpenAI also upgraded the stock to Hold with a $122.00 price target.

See the top stocks recommended by analysts >>

DENTSPLY SIRONA (XRAY)

In a report released today, David Saxon from Needham maintained a Hold rating on DENTSPLY SIRONA. The company’s shares closed last Thursday at $12.71.

According to TipRanks.com, Saxon is a 1-star analyst with an average return of -0.3% and a 36.7% success rate. Saxon covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Irhythm Technologies, and Alphatec Holdings. ;'>

DENTSPLY SIRONA has an analyst consensus of Hold, with a price target consensus of $13.86, which is an 8.2% upside from current levels. In a report released today, TipRanks – Anthropic also upgraded the stock to Hold with a $12.00 price target.

Personalis (PSNL)

In a report released today, Michael Matson from Needham maintained a Buy rating on Personalis, with a price target of $12.00. The company’s shares closed last Thursday at $9.03.

According to TipRanks.com, Matson is a 2-star analyst with an average return of 0.6% and a 44.0% success rate. Matson covers the Healthcare sector, focusing on stocks such as Insight Molecular Diagnostics, Establishment Labs Holdings, and Zimmer Biomet Holdings. ;'>

Currently, the analyst consensus on Personalis is a Strong Buy with an average price target of $11.83.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.